COEPTIS Inc.

About COEPTIS Inc.

Coeptis Therapeutics is a biopharmaceutical company focused on developing innovative cell therapy platforms to improve outcomes for patients with cancer.

Products & Services

Novel Stem Cell Expansion Technology:A strategy focused on advancing stem cell therapies for cancer treatment.

Unmodified Immune Effector Cell Program:A program involving natural killer cells as a therapeutic approach for cancer.

SNAP-CAR:A cell therapy platform utilizing SNAP-CAR technology for targeted cancer treatment.

GEAR-NK (CD38):A specific natural killer cell therapy targeting CD38 for cancer treatment.

Specialties

Cell Therapy Platforms Oncology Stem Cell Expansion Natural Killer Cells CAR-T Therapy

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A Preferred T: - FT: Series A Preferred	A: 10000000 MR: - FA: $10 million FAN: 10000000	D: 2025-02-06 FD: 2025-02-06	1 investors
2	RT: Series A Preferred Stock Offering T: - FT: Series A Preferred Stock Offering	A: 10000000 MR: - FA: $10 million FAN: 10000000	D: 2025-02-01 FD: 2025-02-01	-
3	RT: Series A Preferred T: - FT: Series A Preferred	A: 4300000 MR: - FA: 4.3 million FAN: 4300000	D: 2024-06-20 FD: 2024-06-20	1 investors
4	RT: Underwritten Offering T: - FT: Underwritten Offering	A: 3500000 MR: - FA: $3.5 million FAN: 3500000	D: 2023-06-16 FD: 2023-06-16	1 investors
5	RT: Underwritten Offering T: - FT: Underwritten Offering	A: 3500000 MR: - FA: 3.5 million FAN: 3500000	D: 2023-06-14 FD: 2023-06-14	1 investors

Series A Preferred Latest

2025-02-06

$10.0M

1 investor (Pro only)

Series A Preferred Stock Offering 2025-02-01

$10.0M

Series A Preferred 2024-06-20

$4.3M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Dave Mehalick

Chairman, President and Chief Executive Officer

B

Brian Cogley

Chief Financial Officer

C

Colleen Delaney

Chief Scientific and Medical Officer (Consultant)

C

Christine Sheehy

VP of Compliance and Corporate Secretary

D

Dan Yerace

Director and Vice President of Operations

E

Evren Alici

Head of the Gene and Cell Therapy Group, Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital

View 19 more team members with Pro

Unlock Full Team Directory

Recent News

COEPTIS Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised